With IRS tightening enforcement on dependents and tax credits, families face heightened scrutiny for mistakes on 2024 and 2025 returns
IRVINE, CA / ACCESS Newswire / July 30, 2025 / As the IRS ramps up enforcement in the wake of pandemic-era tax benefits and evolving digital filing tools, parents are being warned that mistakenly claiming the Child Tax Credit (CTC) – even unintentionally – could lead to audits, delayed refunds, or serious financial penalties.
Clear Start Tax, a leading tax resolution firm, is alerting taxpayers to a growing trend in IRS investigations centered around ineligible or duplicate child-related tax credit claims. With billions in credits distributed over the past few years and ongoing pressure to recover erroneous payments, experts say families should be extra cautious when preparing their tax returns – particularly when multiple households or caregivers are involved.
“The Child Tax Credit helped millions of families, but it also opened the door for confusion,” said a spokesperson for Clear Start Tax. “We’re seeing more cases where two parents each claimed the same child, or where someone claimed a dependent they’re no longer eligible for – often without realizing the full consequences.”
A Common Mistake, With Expensive Outcomes
The Child Tax Credit, which provides up to $2,000 per qualifying child, is meant to support low- and middle-income families. However, claiming the credit requires strict adherence to IRS eligibility rules, including proof of residency, relationship, and financial support. In 2025, the IRS is reportedly expanding its use of AI tools to detect inconsistencies and duplicate claims, triggering automated audits and refund delays.
For families navigating custody agreements, blended households, or informal caregiving situations, the rules can be murky – and mistakes are common.
“We’ve had clients come to us after receiving a CP75 letter from the IRS – a notice that flags their return for audit due to a claimed dependent,” said the Clear Start Tax spokesperson. “In some cases, their refund was frozen. In others, they were hit with repayment demands plus interest and penalties.”
According to IRS data, tens of thousands of families are flagged each year for dependent-related discrepancies, many stemming from unclear custody situations or outdated records. In more serious cases, repeated or fraudulent claims can even be referred for criminal investigation.
Prevention Over Penalties
While honest mistakes are not considered fraud, the IRS can still impose steep penalties if it deems a taxpayer was negligent or failed to correct known issues. In some cases, a taxpayer may be barred from claiming the credit for up to two years.
“Parents are often surprised to learn they can lose future eligibility just from one filing error,” said the Clear Start Tax spokesperson. “The best defense is proactive preparation and, if needed, professional guidance before filing.”
For those who’ve already received an IRS letter or notice related to the Child Tax Credit, Clear Start Tax advises acting quickly to avoid escalation. Responding with proper documentation within the deadline window is essential to protect refunds and avoid enforcement action.
By answering a few simple questions, taxpayers can find out if they’re eligible for the IRS Fresh Start Program and take the first step toward resolving their tax debt.
About Clear Start Tax
Clear Start Tax is a nationally recognized tax resolution firm helping individuals and families navigate complex IRS issues, from audits and debt to unfiled returns and penalties. With a focus on client advocacy and long-term financial solutions, the firm has helped thousands of taxpayers achieve relief and regain peace of mind.
Topical Ketamir-2 significantly reduced both acute and inflammatory pain behaviors in animals, demonstrating rapid onset, durable effect, and comparable efficacy to injected morphine across both pain phases
MIAMI, FLORIDA / ACCESS Newswire / July 30, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical company focused on developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced new preclinical data showing that its topical Ketamir-2 cream delivered similar and consistent pain relief compared with injected morphine in a validated animal model of acute and inflammatory pain.
In the study, Ketamir-2 cream was applied topically to the affected area 30 minutes before pain was induced using the formalin model, a widely accepted preclinical method for evaluating both acute and inflammatory pain. In this model, a small amount of formalin (a dilute formaldehyde solution) is injected into the paw, producing two well-characterized phases of pain: an initial acute phase driven by direct nerve activation, followed by a prolonged inflammatory phase associated with central sensitization (a mechanism shared with neuropathic pain). Researchers monitored spontaneous pain-related behaviors-specifically paw licking and paw lifting-using AI-assisted video analysis of 5-minute slots over a 60-minute period.
Topical Ketamir-2 was effective as Injected morphine in both phases, nearly eliminating pain behaviors during the acute phase and maintaining a strong, durable effect throughout the inflammatory phase. These results indicate Ketamir-2’s potential to modulate both peripheral and central pain pathways with topical, localized delivery.
“These findings confirm Ketamir-2’s potential as a next-generation, non-opioid topical treatment for localized pain,” said Erez Aminov, Chairman and CEO of MIRA. “With our oral IND already cleared and a Phase 2a neuropathic pain trial expected to begin by year-end, this topical data meaningfully expands our clinical and commercial strategy. We’re advancing a dual-route platform that can target both systemic and localized pain conditions-offering optionality for patients and value for shareholders.”
Dual-Phase Pain Relief Without Systemic Burden
Unlike systemic analgesics, which circulate throughout the body and may cause unwanted side effects, Ketamir-2’s topical formulation is designed to provide direct, localized pain relief with minimal systemic exposure. Its performance across both acute and inflammatory pain phases supports a broad therapeutic profile-potentially applicable to conditions such as diabetic neuropathy, chemotherapy-induced peripheral neuropathy (CIPN), postherpetic neuralgia, and osteoarthritis.
“What’s remarkable is Ketamir-2’s ability to nearly abolish acute pain behavior while also suppressing inflammation-driven responses,” said Dr. Itzchak Angel, CSA at MIRA. “This dual-phase efficacy is rarely seen with topicals and strongly supports our rationale to continue advancing preclinical studies aimed at treating complex localized pain conditions.”
Addressing an $11.5 Billion U.S. Topical Pain Market
The U.S. topical pain relief market is projected to exceed $11.5 billion by 2025, driven by demand for safer, non-opioid, non-systemic options, according to a report by Research and Markets. Chronic pain affects more than 51 million adults in the U.S., and many of the most prevalent pain conditions-such as osteoarthritis and neuropathy-are localized in nature.
Ketamir-2’s topical formulation is designed to meet this need by offering:
Fast onset of action
Efficacy in both neurogenic and inflammatory pain
Minimal systemic absorption
Non-opioid, non-habit forming mechanism of action
Unlike many pain programs that pursue either systemic or localized delivery, MIRA is developing Ketamir-2 in both oral and topical forms. This dual-path approach may enable clinical evaluation across a broader spectrum of pain conditions-ranging from widespread neuropathic syndromes to localized inflammatory pain. If successful, this strategy could support differentiated product profiles and expand potential treatment opportunities.
A Scalable Non-Opioid Pain Platform
MIRA is currently conducting a Phase 1 clinical trial of oral Ketamir-2 in healthy volunteers. Following FDA clearance of its Investigational New Drug (IND) application, a Phase 2a clinical trial in neuropathic pain is expected to begin later this year in the USA.
The Company is also continuing preclinical development of the topical formulation to further characterize its pharmacological effects and support potential clinical advancement. Together, these efforts reflect a platform strategy designed to address high-burden pain conditions through both systemic and localized approaches.
“As we continue to execute on our clinical and regulatory milestones, we remain focused on unlocking the full value of the Ketamir-2 platform-either through internal advancement or strategic partnership,” added Aminov.
About MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company’s pipeline includes oral drug candidates designed to address significant unmet medical needs in areas such as neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline.
This press release and the statements of MIRA’s management related thereto contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA’s current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA’s control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA’s potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA’s programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 14A filed by MIRA on June 18, 2025, and other SEC filings, which are on file with the SEC at www.sec.gov and on MIRA’s website at https://www.mirapharmaceuticals.com/investors/sec-filings. MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
TORONTO, ON / ACCESS Newswire / July 30, 2025 / Northern Superior Resources Inc. (“Northern Superior” or the “Company“) (TSXV:SUP)(OTCQB:NSUPF)(GR:D9M1) is pleased to announce additional results from its 20,000-metre expansion drilling campaign at the Philibert gold property, located just 9 km from IAMGOLD Corporation’s (“IAMGOLD“) Nelligan project and 60 km southwest of Chibougamau, Quebec (the “Philibert Project“: Northern Superior: 75%, SOQUEM: 25%).
Highlights Include: (Grades uncut; lengths are measured along the drill hole. See Table 1 for details.)
PB-25-490: 11.99 g/t Au over 9.1 metres, including 101.0 g/t Au over 1.0 metre, starting at 104.5 metres – Corsac Fox Hanging Wall Zone;
PB-25-502: 0.73 g/t Au over 46.8 metres, including 1.86 g/t Au over 9.5 metres, starting at 232.7 metres – Corsac Fox Hanging Wall Zone;
PB-25-504: 1.83 g/t Au over 18.8 metres, including 3.02 g/t Au over 10.6 metres, starting at 6.7 metres, and 1.75 g/t Au over 65.0 metres, including 3.92 g/t Au over 17.4 metres, starting at 94.5 metres – Arctic Fox Footwall Zone drilled parallel and down dip of mineralization (see Figure 3); and
PB-25-505: 1.29 g/t Au over 33.0 metres, including 5.71 g/t Au over 1.7 metres, starting at 9.0 metres – Arctic Fox Footwall Zone drilled parallel and down dip of mineralization.
“Today’s results focus on the middle and western extent of the conceptual pit, where we aimed to expand the Corsac Fox Hanging Wall zones. Hole PB-25-490 intersected very high grades near surface, outside of the current conceptual pit, and confirms the opportunity for significant resource expansion in this area. Moreover, drilling has filled in areas previously interpreted as non-mineralized due to sparse historical drilling,” said Simon Marcotte, President and Chief Executive Officer of Northern Superior.
“We are particularly encouraged by PB-25-504 (see Figure 3), which intersected mineralization right at the contact between the bedrock and overburden, just 4.7 metres vertically from surface-demonstrating the near-surface potential of this system. The continued success at the southeast pit, the recent deep high-grade hits, and now this new hanging wall mineralization, all underscore the potential to grow Philibert well beyond the current resource,” he added.
“PB-25-490 stands out with exceptional grade and width in an area where the pit shallows due to sparse historical drilling,” said Adree DeLazzer, Vice President of Exploration for Northern Superior. “Drillholes such as PB-25-502, which intersected 0.73 g/t over 46.5 metres, confirm strong mineralization continuity with meaningful width. These new intersections, located north of the Red Fox and Arctic Fox Footwall zones along the northern wall of the conceptual pit, continue to support our strategy of growing near-surface ounces along the 4-5 km Philibert trend. New structural and geochemical data are significantly enhancing our understanding of this large and evolving gold system,” she added.
Table 1: Significant Drillhole Intersections
DDH ID
From (m)
To (m)
Width (m)
Au Finale (g/t)
Comment
PB-25-490
104.5
113.6
9.1
11.99
Corsac Fox Hanging Wall
including
110.0
111.0
1.0
101.00
Corsac Fox Hanging Wall
PB-25-492
144.0
147.3
3.3
1.87
Corsac Fox Hanging Wall
including
144.8
145.3
0.5
4.84
Corsac Fox Hanging Wall
including
146.8
147.3
0.5
4.99
Corsac Fox Hanging Wall
PB-25-494
149.6
151.1
1.5
6.54
Corsac Fox Hanging Wall
and
166.3
172.0
5.7
1.15
Corsac Fox Hanging Wall
and
195.0
201.0
6.0
1.15
Corsac Fox Hanging Wall
PB-25-500
244.0
259.5
15.5
0.94
Corsac Fox Hanging Wall
including
244.0
245.5
1.5
7.67
Corsac Fox Hanging Wall
and
285.5
287.7
2.2
7.11
Corsac Fox Hanging Wall
including
285.5
286.7
1.2
10.68
Corsac Fox Hanging Wall
PB-25-502
232.7
279.5
46.8
0.73
Corsac Fox Hanging Wall
including
270.0
279.5
9.5
1.86
Corsac Fox Hanging Wall
PB-25-504*
6.7
25.5
18.8
1.83
Arctic Fox Footwall
Including*
12.4
23.0
10.6
3.02
Arctic Fox Footwall
and*
94.5
159.5
65.0
1.75
Arctic Fox Footwall
Including*
101.6
119.0
17.4
3.92
Arctic Fox Footwall
Including*
130.7
133.0
2.3
4.64
Arctic Fox Footwall
Including*
146.3
147.3
1.0
7.81
Arctic Fox Footwall
PB-25-505*
9.0
42.0
33.0
1.29
Arctic Fox Footwall
Including*
19.9
21.6
1.7
5.71
Arctic Fox Footwall
Grades have not been capped in the averaging and intervals are reported as drill thickness. True widths are estimated at 70% to 90%, except for drill holes marked with “*” which were drilled down dip and parallel to mineralization, with true widths estimated at 40% to 60%. Intersections are determined using 0.3 g/t Au cut-off and no more than 15 metres of consecutive dilution. If an intersection is 1 metre or less, dilution under 0.1 g/t Au may be used to determine a 2-metre intersection.
Figure 2: View looking northeast and dipping at 40 degrees – 200 metres width of Corsac Fox HW zone showing composite grade in Au g/t and highlights from press release labeled.
Figure 3: Picture of drill hole PB-25-504: 65.0 metres of 1.75 g/t Au starting at 94.5 metres including 17.4 metres of 3.92 g/t Au starting at 101.6 metres. Partial view of the intervale from 91.0 metres to 107.7 metres.
Drilling Results The current drill program tested the Corsac Fox Hanging Wall over a 750-metre strike length where historical drill density was low (see figures 1 and 2). Results from ten drill holes show that the Hanging Wall domains have a different style of mineralization to the well known footwall domain. The Hanging Wall domains are caracterized by a high-grade vein-style gold and broader envelopes near the northern wall of the conceptual pit (see tables 1 and 2). The hanging wall domains show a strong nugget effect compared to the footwall zones, and visible gold is frequently observed.
PB-25-490, located approximately 80 metres vertically from surface and 60 metres below the pit shell, intersected 11.99 g/t Au over 9.1 metres including 101.0 g/t Au over 1.0 metre. Another three drill holes tested the area where the conceptual pit shallows to surface over approximately 200 metres. PB-25-492, located 60 metres west of PB-25-490, returned 1.87 g/t Au over 3.3 metres. PB-25-489, situated 90 metres east of PB-25-490, intersected several narrow, higher-grade intervals, including 4.82 g/t Au over 1.5 metres, 2.17 g/t Au over 2.4 metres, and 4.15 g/t Au over 1.2 metres. PB-25-494, drilled 120 metres west of PB-25-490, returned multiple intervals from the hanging wall zones, including 6.54 g/t Au over 1.5 metres, 1.15 g/t Au over 5.7 metres, and 1.15 g/t Au over 6.0 metres.
Two drill holes were completed from the same setup approximately 600 metres west of PB-25-490, slightly off the main azimuth, to test the continuity of mineralization within the hanging wall zones in the western portion of the pit. PB-25-502 returned a broad intercept of 0.73 g/t Au over 46.8 metres, including a higher-grade interval of 1.86 g/t Au over 9.5 metres, highlighting strong potential for continuous, near-surface mineralization. PB-25-500 intersected 0.94 g/t Au over 15.5 metres, including 7.67 g/t Au over 1.5 metres, as well as additional higher-grade, narrower intervals such as 7.11 g/t Au over 2.2 metres and 10.68 g/t Au over 1.2 metres.
Two drill holes, PB-25-504 and PB-25-505, were completed to test the Arctic Fox Footwall zones down-dip of known mineralization, each drilled at different orientations to collect critical structural data and improve our geological understanding of the system. PB-25-504 intersected multiple broad and high-grade intervals including 18.8 metres grading 1.83 g/t Au from 6.7 metres, with a higher-grade core of 10.6 metres of 3.02 g/t Au. A second major zone returned 65.0 metres of1.75 g/t Au from 94.5 metres depth, including 17.4 metres of 3.92 g/t Au, with sub-intervals such as 4.0 metres of 5.37 g/t Au. PB-25-505 also intersected a broad mineralized zone of 33.0 metres of 1.29 g/t Aufrom9.0 metres, including a higher-grade section of 1.7 metres at 5.71 g/t Au. These holes confirm the presence of continuous and robust mineralization at the bedrock interface in the Arctic Fox Footwall and provide valuable data for refining the deposit’s structural model. Less historic work has been completed on the northern hanging wall domains, and the geological model and mineralization controls are currently being investigated using new structural core orientation and geochemical data to further refine the model.
The team is developing a follow-up drilling program to further investigate the higher grade near-surface mineralization as well as at depth to increase the ounces in the resource pit and potentially add an underground component to the resource.
Table 2: Drillhole Intersections for entire Press Release
DDH ID
From (m)
To (m)
Width (m)
Au Finale (g/t)
Comment
PB-25-485
75.0
78.2
3.2
0.39
Corsac Fox Hanging Wall
and
310.9
313.7
2.8
1.55
Corsac Fox Hanging Wall
PB-25-487
54.0
74.2
20.2
0.26
Corsac Fox Hanging Wall
including
60.0
64.5
4.5
0.40
Corsac Fox Hanging Wall
and
88.2
88.9
0.7
1.58
Corsac Fox Hanging Wall
PB-25-489
83.9
85.4
1.5
4.82
Corsac Fox Hanging Wall
and
103.6
106.6
3.0
1.53
Corsac Fox Hanging Wall
and
135.0
137.4
2.4
2.17
Corsac Fox Hanging Wall
including
135.0
135.9
0.9
5.00
Corsac Fox Hanging Wall
and
147.3
148.5
1.2
4.15
Corsac Fox Hanging Wall
and
157.8
159.3
1.5
1.97
Corsac Fox Hanging Wall
and
352.0
362.0
10.0
0.28
Arctic Fox Footwall
PB-25-490
49.1
56.0
6.9
0.57
Corsac Fox Hanging Wall
and
104.5
113.6
9.1
11.99
Corsac Fox Hanging Wall
including
110.0
111.0
1.0
101.00
Corsac Fox Hanging Wall
PB-25-492
144.0
147.3
3.3
1.87
Corsac Fox Hanging Wall
including
144.8
145.3
0.5
4.84
Corsac Fox Hanging Wall
including
146.8
147.3
0.5
4.99
Corsac Fox Hanging Wall
PB-25-494
135.1
141.5
6.4
0.40
Corsac Fox Hanging Wall
and
149.6
151.1
1.5
6.54
Corsac Fox Hanging Wall
and
166.3
172.0
5.7
1.15
Corsac Fox Hanging Wall
and
195.0
201.0
6.0
1.15
Corsac Fox Hanging Wall
and
386.5
391.6
5.1
0.32
Corsac Fox Hanging Wall
and
487.7
498.9
11.2
0.81
Corsac Fox Hanging Wall
PB-25-497
182.0
183.0
1.0
1.53
Corsac Fox Hanging Wall
and
207.0
210.0
3.0
0.77
Corsac Fox Hanging Wall
and
228.4
231.0
2.6
0.67
Corsac Fox Hanging Wall
including
230.0
230.5
0.5
2.86
Corsac Fox Hanging Wall
and
503.2
513.5
10.3
1.12
Arctic Fox Footwall
including
507.2
510.5
3.3
2.67
Arctic Fox Footwall
PB-25-499
204.0
205.5
1.5
0.40
Corsac Fox Hanging Wall
PB-25-500
232.0
233.5
1.5
2.88
Corsac Fox Hanging Wall
and
244.0
259.5
15.5
0.94
Corsac Fox Hanging Wall
including
244.0
245.5
1.5
7.67
Corsac Fox Hanging Wall
and
285.5
287.7
2.2
7.11
Corsac Fox Hanging Wall
including
285.5
286.7
1.2
10.68
Corsac Fox Hanging Wall
and
296.7
300.6
3.9
0.56
Corsac Fox Hanging Wall
and
338.3
339.8
1.5
0.47
Corsac Fox Hanging Wall
and
355.2
374.3
19.1
0.57
Corsac Fox Hanging Wall
and
399.8
401.3
1.5
1.74
Corsac Fox Hanging Wall
and
441.2
442.6
1.4
0.72
Arctic Fox Footwall
and
527.5
529.0
1.5
1.41
Arctic Fox Footwall
PB-25-502
232.7
279.5
46.8
0.73
Corsac Fox Hanging Wall
including
270.0
279.5
9.5
1.86
Corsac Fox Hanging Wall
and
335.0
355.0
20.0
0.46
Corsac Fox Hanging Wall
including
335.0
336.0
1.0
3.02
Corsac Fox Hanging Wall
and
402.5
416.0
13.5
0.75
Corsac Fox Hanging Wall
and
442.5
453.0
10.5
0.41
Corsac Fox Hanging Wall
PB-25-504
6.7
25.5
18.8
1.83
Arctic Fox Footwall
including
12.4
23.0
10.6
3.02
Arctic Fox Footwall
and
64.0
66.0
2.0
1.64
Arctic Fox Footwall
and
81.5
83.8
2.3
0.50
Arctic Fox Footwall
and
94.5
159.5
65.0
1.75
Arctic Fox Footwall
including
101.6
119.0
17.4
3.92
Arctic Fox Footwall
including
130.7
133.0
2.3
4.64
Arctic Fox Footwall
including
146.3
147.3
1.0
7.81
Arctic Fox Footwall
PB-25-505
9.0
42.0
33.0
1.29
Arctic Fox Footwall
including
19.9
21.6
1.7
5.71
Arctic Fox Footwall
and
66.0
74.9
8.9
0.75
Arctic Fox Footwall
Grades have not been capped in the averaging and intervals are reported as drill thickness. True widths are estimated at 70% to 90% except for drill holes marked with “*” which were drilled down dip and parallel to mineralization with true widths at 40% to 60%. Intersections are determined using a 0.3 g/t Au cut-off and no more than 10 metres of consecutive dilution. If an intersection is 1 metre or less, dilution under 0.1 g/t Au may be used to determine a 2-metre intersection.
The Chibougamau Gold Camp The Chibougamau Gold Camp is rapidly emerging as one of the world’s most sought-after gold destinations with several complementary gold resources reaching viable scale. In recent years, these critical assets were divided amongst five different companies. Today, largely due to Northern Superior’s acquisitions and corporate transactions,[1] ownership has been streamlined, with only IAMGOLD and Northern Superior holding these assets. The proximity of these deposits to each other makes them ideally suited to feed a single mill, and their consolidation enhances their viability, thereby increasing their value.
Below is a table showing the resources of the camp having been formalized to date.
Note: see NI-43-101 information below in notes 2, 3, 4, and 5.
Qualified Person (“QP”) The technical content and drilling results contained in this news release have been prepared in accordance with National Instrument 43-101 Standards of Disclosure for Mineral Projects (“NI 43-101“) and have been reviewed and approved by Ms. Melanie Pichon, P.Geo., Senior Geologist for Northern Superior. Ms. Pichon is a QP under the NI 43-101 and is not considered independent.
Northern Superior adheres to strict protocols following the NI 43-101 best practices when conducting exploration works. Sampling and assay results are monitored with strict QAQC protocols. Drilled core is processed and assayed in Northern Superior’s facilities in Chapais, Quebec. Core samples (half core) are transported to Agat Laboratory in Val d’Or.Samples are analyzed by fire assay with a 50-gram charge with an Atomic Absorption (AA) finish. Samples returning assay values over 10.0 grams are re-assayed with a gravimetric finish. QAQC consists of 4% of blank material, certified standards and duplicates inserted in the assay sequences by Northern Superior.
Corporate Matters On July 28, 2025, the Company entered an agreement with CanaCom Group (“CanaCom“), pursuant to which CanaCom agreed to provide digital content, marketing, and media distribution services to the Company. Pursuant to the terms of the agreement, such marketing services are to be provided over a 12-month period, commencing on August 1, 2025, for a monthly fee of C$7,500, plus applicable taxes. CanaCom is a full-service marketing agency based in Toronto, Ontario. CanaCom provides digital marketing awareness via advertising through its fully owned platform theDeepDive.ca, which includes both video and written content coverage of Canadian small-cap companies. CanaCom operates as an arm’s length service provider to the Company and is owned by Mr. Jordan Lutz.
About Northern Superior Resources Inc. Northern Superior is a gold exploration company focused on the Chibougamau Camp in Québec, Canada. The Company has consolidated the largest land package in the region, with total land holdings currently exceeding 68,000 hectares. The main properties include Philibert, Hazeur (adjacent to Philibert), Lac Surprise, Chevrier, Croteau, Monster Lake East, and Monster Lake West. Northern Superior also owns 56% of ONGold Resources Ltd. (TSXV:ONAU)(OTCQX:ONGRF) which is advancing promising exploration assets in Northern Ontario and Manitoba, including the district scale TPK Project and Monument Bay; Agnico Eagle Mines Limited owns 15% of ONGold Resources Ltd.
The Philibert Project is located 9 km from IAMGOLD Corporation’s Nelligan[2] Gold project. Philibert hosts a maiden 43-101 inferred resource of 48.46 Mt at 1.10 g/t Au for 7.88 Mt at 1.10 g/t Au for 1,708,800 ounces Au and an indicated resource of 278,900 ounces Au.[3] Northern Superior holds a majority stake of 75% in the Philibert Project, with the remaining 25% owned by SOQUEM, and retains an option to acquire the full 100% ownership of the project. Chevrier hosts an inferred mineral resource of 15.7 Mt at 1.30 g/t Au for 652,000 ounces Au (underground and open pit) and an indicated mineral resource of 6.4 Mt at 1.26 g/t Au for 260,000 ounces Au.[4] Croteau hosts an inferred mineral resource of 11.6 Mt at 1.7 g/t Au for 640,000 ounces Au.[5] Lac Surprise hosts the Falcon Zone Discovery, interpreted to be the western strike extension of IAMGOLD Corporation’s Nelligan Gold project.
Northern Superior is a reporting issuer in British Columbia, Alberta, Ontario and Québec, and trades on the TSXV under the symbol SUP and the OTCQB Venture Market under the symbol NSUPF. For further information, please refer to the Company’s website at www.nsuperior.com or the Company’s profile on SEDAR+ at www.sedarplus.ca.
About SOQUEM SOQUEM, a subsidiary of Investissement Québec, is dedicated to promoting the exploration, discovery, and development of mining properties in Québec. SOQUEM also contributes to maintaining strong local economies. Proud partner and ambassador for the development of Québec’s mineral wealth, SOQUEM relies on innovation, research, and strategic minerals to be well-positioned for the future.
Northern Superior Resources Inc. on Behalf of the Board of Directors Simon Marcotte, CFA, President and Chief Executive Officer
Contact Information Katrina Damouni Director – Corporate Development Tel: +44 7795 128583 (Mobile/WhatsApp) info@nsuperior.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Cautionary Note Regarding Forward-Looking Information This news release contains “forward-looking information” within the meaning of the applicable Canadian securities legislation that is based on expectations, estimates, projections and interpretations as at the date of this news release. The information in this news release that is not a historical fact may be “forward-looking information”. Any statement that involves discussions with respect to predictions, expectations, interpretations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “interpreted”, “management’s view”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information and are intended to identify forward-looking information. This forward-looking information is based on reasonable assumptions and estimates of the management of Northern Superior, at the time it was made, involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the companies to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information. Although the forward-looking information contained in this news release is based upon what management believes, or believed at the time, to be reasonable assumptions, the parties cannot assure shareholders and prospective purchasers of securities that actual results will be consistent with such forward-looking information, as there may be other factors that cause results not to be as anticipated, estimated or intended, and neither party nor any other person assumes responsibility for the accuracy and completeness of any such forward-looking information. Neither party undertakes, and assumes no obligation, to update or revise any such forward-looking statements or forward-looking information contained herein to reflect new events or circumstances, except as may be required by law.
[1] Including Northern Superior’s acquisitions of Genesis Metals Corp. and Royal Fox Gold Inc.
[2] “lAMGOLD Announces Significant Increase in Nelligan Ounces & Update of Global Mineral Reserves and Resources”;
IAMGOLD reports increase in mineral reserves and resources at existing assets, with increase in resources at Gosselin; IAMGOLD Corporation News Release dated February 15, 2024, October 23, 2024, and February 20, 2025. Note that the technical and scientific information disclosed from neighboring properties does not apply to any other properties of the area.
[3]Northern Superior announces 1,708,809 gold ounces in inferred category and 278,921 gold ounces in indicated category at 1.10 g/t in maiden NI 43-101 pit constrained resource estimate at Philibert; Northern Superior’s press release dated August 08, 2023.
[4] NI 43-101 Technical Report Mineral Resource Estimation for the Chevrier Main Deposit, Chevrier Project Chibougamau, Quebec, Canada, October 20, 2021, Prepared in accordance with NI 43-101 by Lions Gate Geological Consulting Inc. IOS Services Géoscientifiques Inc. for Northern Superior.
[5]Chalice Gold Mines Limited and Northern Superior Resources Inc. Technical Report on the Croteau Est Gold Project, Québec, September 2015, Prepared in accordance with NI 43-101 by Optiro Pty Ltd (“Optiro”) to Chalice Gold Mines Limited and Northern Superior.
Boost beer cave and heavy product sales with Planniq Strong®, high-capacity merchandising system from ImageWorks Display
WINSTON-SALEM, NC / ACCESS Newswire / July 30, 2025 / Retail merchandising leader ImageWorks Display® has made it easier than ever to boost beer cave and heavy product sales with its Planniq Strong® high-capacity merchandising system. Planniq Strong delivers one of the fixture industry’s highest weight capacities with 2,000-pounds-per-four-foot-sections to help convenience and grocery retailers stock and sell beer, beverages and bulky products with confidence.
ImageWorks CEO Justin Raney said Planniq Strong fixtures were designed to maximize in-store sales of heavy product in a format previously unavailable to convenience and grocery store retailers. “Conventional convenience store shelves and fixtures were never designed to handle the heaviest merchandise,” said Raney. “Increasingly though, that’s what shoppers are seeking. They want more beverage options, they’re interested in seasonal merchandise displayed outdoors, and they want to save time by buying heavy merchandise like pet food or automotive supplies in a more convenient retail setting.”
“ImageWorks has removed that limitation with our Planniq Strong system,” Raney adds. “Planniq Strong opens up a range of new revenue opportunities for retailers seeking to maximize beer cave, seasonal and heavy product sales. The system is durable enough to add capacity outdoors while also making beer cave and other indoor merchandise more accessible to shoppers.”
Planniq Strong fixtures build upon the foundational structures established by the ImageWorks Display collection of Planniq center store fixtures. The Planniq Strong system’s clean design and sleek black finish integrate into any retail environment, including those with the ImageWorks Xulta line of back bar displays. Planniq Strong fixtures are available in stock in 60″ or 72″ heights, and your choice of 24″, 36″ or 48″ center-to-center fixture widths.
Like other Planniq center store displays, the Planniq Strong line features your choice of flat wire or sheet metal shelving. The system’s post-free design offers a clear line of site for enhanced product visibility and accessibility. Corner kits are available, as well as optional wire and flip headers.
Raney notes that ImageWorks Display continues to innovate in beer cave and heavy product merchandising, with several new products in late-stage development. Like its existing Planniq and Xulta lines, the new ImageWorks offerings are designed to deliver a total store solution to create an elevated, cohesive environment that attracts customers and increases sales.
Since 1996, ImageWorks Display® has been creating both in-stock and custom retail display solutions within the merchandising industry. Considered a “total store solution” provider with unique expertise and offerings for whole-store integration, ImageWorks Display is known for its high-quality materials, performance engineering, innovative designs, and end-to-end customer service – service that places the client at the center of decision-making.
Their customer-centric business philosophy, along with their top-quality display products, have earned ImageWorks Display the privilege of being in many small-business and large-chain convenience stores throughout the U.S. Their back bar Xulta Impact® and Xulta Classic® products are the standard-setting solutions within the display industry.
Their center store gondola solution line includes Planniq Tech®, Planniq Core®, Planniq Strong, Planniq Lock®, Planniq Bev®, and Planniq Queue™. Both the Xulta back bar and Planniq center store product lines maximize dynamic retail environments with elevated and cohesive designs, resulting in increased sales and improved shopper experiences. Another area in which ImageWorks excels is the practical application of product pusher technology. Their pushers are known in the industry as the ones that never break. Strong product pushers and strong pusher tactics combine to help clients increase both sales and profitability.
Many clients choose to co-create custom solutions with the ImageWorks Display engineering and design teams. Clients see ImageWorks Display as an extension of their own merchandising team. This design collaboration encourages innovation and creativity, while resulting in highly effective display solutions that stand the test of time.
ImageWorks Display offers premium quality fixtures for a range of retail environments, along with lifetime product support, best-in-class supply chain management, and robust client service for every client partnership it enters. Nothing is more important than enduring relationships with loyal clients. This dedication is at the core of what drives their success. And it’s also what assures the success of their highly valued clients.
Contact: Anne M. Berg, President Vyway® Market & Brand Strategy anne@vyway.com | 651-271-1111
At The Iskandar Complex Hernia Center, where innovation and surgical excellence go hand-in-hand, a groundbreaking study out of Northwestern University has sparked conversation about a future where hernias may not always require surgical correction. The study, titled “Estrogen Receptor Alpha Ablation Reverses Skeletal Muscle Fibrosis and Inguinal Hernias,” identifies a promising new direction in hernia research: targeting hormone receptors to potentially prevent or mitigate hernia formation. Specifically, the researchers found that estrogen receptor alpha (ESR1) plays a critical role in muscle fibrosis, a process that can weaken abdominal tissue and lead to inguinal hernias. This early research, conducted in a mouse model, suggests that blocking ESR1 with medications like Fulvestrant may help reverse or reduce fibrosis, thus addressing a key factor in hernia development. The Iskandar Complex Hernia Center examines the study and results in a new article titled “Preventing Hernias With Drugs: Is It In Our Future?“
While surgery remains the only proven treatment for inguinal hernias today, this study raises important questions about whether drug therapy could one day support or enhance surgical outcomes—or in select cases, delay the need for surgery altogether. The findings have caught the attention of leading hernia surgeons like Dr. Mazen Iskandar, founder of The Iskandar Complex Hernia Center, who sees the potential in combining medical and surgical approaches for more personalized and effective treatment. As a specialist in complex and recurrent hernias, Dr. Iskandar closely monitors developments like these to evaluate how they might be responsibly integrated into clinical practice over time.
In the Aromhum mouse model used in the study, researchers observed that an estrogen receptor (ESR1) triggers muscle fibrosis, aka scar tissue in the muscles, which can weaken the abdominal walls, potentially leading to inguinal hernias. When researchers blocked ESR1 using Fulvestrant, an estrogen receptor antagonist already approved for use in other medical conditions, they saw measurable improvement in tissue quality and a reduction in hernia severity after just a week of treatment. Though these findings are preliminary and limited to animal models, they open the door to a new way of thinking about hernia care—one that targets the underlying biology of the condition rather than just repairing its physical effects.
Dr. Iskandar notes that while it is far too early to suggest that medications could replace surgery, these discoveries offer real potential for improving outcomes. In theory, using estrogen receptor blockers before surgery could optimize the condition of the tissue, possibly making surgical repair easier and reducing recurrence rates. Postoperative use could support better healing by continuing to limit fibrosis during the critical recovery phase. For patients with especially complex or recurrent hernias, this kind of medical management may someday serve as a bridge to surgery or a supportive tool in reducing complications. That said, Dr. Iskandar emphasizes that rigorous human trials will be necessary before any hormone-based therapies can be offered as part of standard treatment protocols.
The implications of this research extend beyond theoretical curiosity. Inguinal hernias are among the most common hernia types, particularly in men, and represent a significant surgical burden in healthcare systems across the globe. These hernias occur when abdominal contents push through a weakened area of the lower abdominal wall, often resulting in pain, bulging, and a progressive worsening of symptoms. At The Iskandar Complex Hernia Center, patients frequently present with advanced or recurrent hernias, often requiring specialized techniques such as robotic-assisted repair or complex open surgery. Any development that could improve the quality of the abdominal wall tissue before surgery or prevent the degradation of muscle layers over time could have meaningful benefits for patients and reduce the need for additional interventions down the line.
The center’s commitment to staying at the forefront of hernia care is what makes this research so relevant to its ongoing mission. Dr. Iskandar explains that innovation in surgery doesn’t just mean refining technique—it also involves evaluating new scientific evidence, assessing risks, and exploring how evolving therapies can fit into safe, effective treatment plans. If human studies confirm their benefits in reducing fibrosis or improving surgical outcomes, these medications could one day be prescribed as part of a hernia management protocol. However, until that time, surgery remains the gold standard.
This distinction is critical for patients currently facing hernia symptoms. Hernias do not resolve on their own, and delaying evaluation or treatment can lead to complications, including bowel obstruction or strangulation. At The Iskandar Complex Hernia Center, early intervention allows for more treatment options and better overall outcomes. Dr. Iskandar encourages individuals experiencing symptoms—such as a bulge in the groin or abdomen, persistent discomfort, or worsening pain during activity—to schedule a consultation. Even as the field explores exciting new directions, the center continues to offer evidence-based, personalized surgical care for every patient.
The center also emphasizes the importance of education in helping patients navigate new developments in medical research. Too often, headlines can give the impression that new treatments are just around the corner when, in fact, they are years away from clinical use. Dr. Iskandar believes in transparency and communication, ensuring that patients understand both the current standard of care and the potential of future therapies without fostering false hope or premature conclusions. This balance of optimism and realism is part of what sets the center apart and earns the trust of patients throughout the region.
The Iskandar Complex Hernia Center remains committed to offering the highest standard of hernia care, grounded in precision, expertise, and a patient-centered approach. As the conversation about preventing hernias with drugs evolves, the center continues to lead by combining scientific awareness with surgical mastery. For patients, this means not only receiving the best possible care today but also having access to forward-thinking strategies that may shape the future of hernia treatment.
GREENSBORO, NC—Jeffrey Segal, MD, JD, a medico-legal expert and the founder of Medical Justice, is calling attention to a landmark federal court ruling that struck down the Department of Health and Human Services’ (HHS) attempt to broaden HIPAA obligations for routine website analytics in a recent blog, “Court Rebukes HHS, Ruling it Over-Reached with HIPAA and New Edicts on Tracking Technology.”
In the blog, Dr. Segal details how the U.S. District Court for the Northern District of Texas rejected HHS’s Online Tracking Bulletin—both its original 2022 version and the 2023 revision—concluding that the agency exceeded its statutory authority. At stake was whether a combination of an IP address and a visit to a public-facing healthcare webpage—what HHS dubbed the “Proscribed Combination”—should automatically be treated as “individually identifiable health information” (IIHI) and therefore trigger the full weight of the HIPAA Privacy Rule. Judge Mark Pittman’s decision plainly states that an inferred link between a visitor and a medical condition “falls far short of what the IIHI definition requires,” undercutting HHS’s attempt to regulate common web tracking tools that every modern business relies on for analytics and site optimization.
“This ruling reinforces a critical boundary: regulators can’t simply rewrite definitions to suit a preferred policy outcome,” Dr. Segal said. “HIPAA already draws clear lines around what constitutes protected health information. Stretching those lines to cover anonymous web-traffic data was never going to survive judicial scrutiny, and the court’s opinion makes that crystal clear.”
The lawsuit—brought by the American Hospital Association (AHA), the Texas Hospital Association, Texas Health Resources, and United Regional Health Care System—was hardly niche. Seventeen additional state hospital associations and 30 individual hospitals and health systems filed amicus briefs, highlighting the nationwide concern that HHS’s guidance would force providers either to disable essential analytics tools or risk crippling civil penalties.
In its opinion, the court focused on statutory text rather than technical minutiae. IIHI, by law, must both relate to an individual’s health, care, or payment for care and reasonably identify that individual. A public website visit, even paired with an IP address, fails that test because motive is unknowable without soliciting it.
As Dr. Segal notes, “Identity plus Query does not equal Diagnosis.” Absent an affirmative disclosure—such as a patient logging into a secure portal—mere metadata cannot be forced into the IIHI box. The court also criticized HHS for creating compliance impossibilities: covered entities would be expected to divine whether each visitor was researching a personal condition, a family member’s illness, or simply reading out of curiosity. Judge Pittman wrote that “HIPAA doesn’t require clairvoyance,” adding that executive oversteps, even in seemingly small bulletins, erode constitutional checks on administrative power.
For physicians and hospital systems, the ruling offers immediate relief. Standard tools like Google Analytics, Meta pixels, or other third-party platforms can continue collecting de-identified traffic data on public pages—content about procedures, surgeon bios, wellness tips, and more—without automatically inviting HIPAA penalties.
Dr. Segal cautions, however, that this is not a license to ignore cybersecurity or privacy best practices. “We still advise members to use encryption, data-minimization, and robust business-associate agreements where PHI is truly in play,” he said. “What the court rejected was HHS’s attempt to label everything PHI by default. Common-sense safeguards remain essential, but they should be grounded in the statute, not in regulatory wish-casting.”
Had the bulletin stood, many hospitals would have faced multimillion-dollar costs to build bespoke analytics systems or forego the insights necessary to improve content, search visibility, and appointment conversions. Dr. Segal explains: “Restricting basic analytics would have pushed healthcare further behind other industries in digital engagement—ironic for regulations meant to protect patients.”
Still, Dr. Segal urges caution: “This isn’t the end of the story. Plaintiffs prevailed because the guidance clashed with plain statutory language. Regulators may try again through Congress or more tailored rulemaking. We’ll be ready to review, comment, and, if needed, challenge overreach.” He encourages physicians to remain vigilant about privacy obligations, especially on patient portals, telehealth platforms, and appointment-booking forms where real PHI is exchanged.
For nearly two decades, Medical Justice has helped doctors navigate the intersection of medicine, law, and technology—from HIPAA compliance and credentialing disputes to internet-based reputation attacks. Its protection plans and eMerit online reputation management program help prevent medico-legal headaches before they escalate. “We protect you and your reputation, proactively,” Dr. Segal said. “This ruling validates the importance of challenging regulatory excesses that hinder, rather than help, quality care.”
Healthcare professionals seeking guidance on HIPAA compliance or broader medico-legal risk management can schedule a complimentary 15-minute consultation on the Medical Justice website.
In Home Flooring is rolling out new improvements in hardwood floor installations and refinishing, showing their commitment to improving flooring experiences for Denver residents. Their comprehensive overview of services can be explored at inhomeflooringdenver.com where potential clients can review a diverse selection of flooring materials and expert installation services. Under the leadership of Jillian Rowe, who has over ten years in the flooring industry, the emphasis is on top-notch craftsmanship and customer happiness.
Specializing in various types of flooring such as hardwood, laminate, and tile, In Home Flooring goes beyond simply selling products. Their focus is on precise, long-lasting installations. They use advanced tools and techniques to ensure each floor fits perfectly into the client’s home.
“Our mission is to transform spaces with beautiful and durable flooring solutions. We take pride in every aspect of our work, from the selection of materials to the final installation,” said Jillian Rowe, owner of In Home Flooring. She went on to explain, “We understand that a floor is not just about looks but also about functionality and how long it lasts. Our skilled team works closely with clients to achieve the perfect balance. More details on our services and craftsmanship can be found on our website.”
When it comes to Hardwood Floor Installation with In Home Flooring, the process is designed to fit individual needs. It begins with a detailed consultation where style preferences and functional requirements are discussed. Flooring material choices are made together with clients, offering options like solid oak, engineered hardwood, and eco-friendly finishes.
In Home Flooring also places great importance on its refinishing services. They use dustless hardwood refinishing tools to minimize disruption to the client’s daily life while making the floor look better and last longer. Refinishing enhances the appearance and provides protection against wear and tear, lengthening the floor’s lifespan.
Understanding the need for flexibility and convenience, In Home Flooring Denver offers in-studio, in-home, and virtual consultations, allowing clients to choose what suits them best. Their services are available in many Denver areas, including Arvada, Aurora, Boulder, and Highlands Ranch.
Their service range also includes specialized repair work. This involves fixing any issues, ensuring even surfaces through sanding, and replacing water-damaged boards when needed. Each process is carried out with care to ensure top-quality results.
Jillian Rowe points out the great importance they place on customer relationships at In Home Flooring. “Our dedicated customer support team is here to assist at every step. From initial consultation to final installation, we prioritize clear and open communication to deliver outstanding flooring solutions tailored to each customer’s unique needs,” she shared.
In Home Flooring’s promise to sustainability shows in their eco-friendly options and responsible installation methods. They make sure every floor is installed not only with attention but also with environmental care in mind. Visit our site for more comprehensive insights into our eco-friendly initiatives and financing options.
In Home Flooring also offers transparent pricing and flexible financing plans. This approach makes top-quality flooring accessible to more people, accommodating various financial situations. The company shares pricing details openly and provides multiple payment options to help manage costs effectively. For detailed information on pricing, clients are encouraged to visit our online resources.
With a wide range of services, careful attention to detail, and true commitment to quality, In Home Flooring is a leading provider of flooring solutions in Denver. Their comprehensive services and understanding of client needs highlight their ongoing success. As they keep innovating and expanding their services, In Home Flooring continues to be a trustworthy partner for anyone looking to improve their space with quality flooring solutions.
Mindmachines.com has rolled out an upgraded version of their ROSHIwave IN-SIGHT Mind Machine. This portable high tech meditation device is aimed at enhancing mental well-being by leading users into deep meditative states with ease.
The device bridges the gap between modern science and traditional meditation. It’s packed with features intended to deepen relaxation experiences. One of its core elements, the brainwave dieentrainment machine, helps users reach a state of calm similar to that of a zen monk. The pROSHI neurodynamnic activator, a new addition, offers a wider range of experiences that reduce stress and improve mental clarity without requiring any conscious effort.
Fred Williams from Mindmachines.com says, “Our goal was to make a tool that makes the benefits of deep meditation accessible to everyone. With the pROSHI neurodynamnic activator in our device, users can easily find a calm state of mind, making it useful not just for meditation professionals but for anyone curious about the practice.”
The redesigned ROSHIwave IN-SIGHT acts like a “Digital Compass” for the brain. It uses a process called Brainwave DisEntrainment through Photostimulation. This process involves using flickering lights that steer the brain into healthier states, helping users break free from repetitive cycles that can hinder mental performance. With services such as Light Sound Mind Machine Brainwave Entrainment, various brainwave states can be achieved in just minutes, including relaxation, meditation, and even enhanced learning. This personalized approach appeals to everyone from athletes looking to enhance performance to individuals interested in behavior change and better learning.
Mindmachines.com has made the device practical and easy to use. With the inclusion of RoshiView Glasses, which have 6 side-firing RGB LEDs per eye, users can fully immerse themselves in the device’s stimulation while seeing their surroundings. The advanced Brainwave Technology on offer continues to support the demands of modern life.
While it’s not a medical device, the ROSHIwave IN-SIGHT promotes personal accomplishments by creating an environment suited for quality meditation and mental wellness. Its design makes it small and easy to carry, similar to an old-school MP3 player. This makes it perfect for people with busy lives who still want to include meditation in their routines.
Mindmachines.com has a strong reputation in brainwave entrainment technology. With this release, they continue to strengthen their standing by providing a product that offers not only personal peace but potential boosts in cognitive and emotional stability. This includes robust tools and methods such as the Frequency Following Response (FFR) to enable users to achieve specific brainwave states.
Frequent users have benefitted from additional therapeutic tools provided by Mindmachines.com for relaxation and enhanced learning among other achievements.
Fred Williams adds, “We recognize the difficulties people face today, and we’re committed to offering tools that help them find mental well-being. The ROSHIwave IN-SIGHT, with its pROSHI neurodynamnic activator, shows our dedication to advancing brainwave technology.”
Active in the brain-machine interface community, Mindmachines.com keeps pushing for advancements in meditation tech. By sharing the ROSHIwave worldwide, they’re committed to spreading the benefits of meditation and neurofeedback to a larger audience, reinforcing their role in wellness technology.
Mindmachines.com operates as an online distributor of brainwave entrainment technology, AVS stimulation devices, EEG neurofeedback equipment, and meditation machines. The website, managed by Av3X LLC, also provides access to the ROSHIwave self-meditation device. For more details about this high tech meditation device, visit mindmachines.com.
New offering provides brands with deeper insights, greater cultural fluency and future-ready planning tools.
NEW YORK CITY, NY / ACCESS Newswire / July 29, 2025 / Target 10, the leading LGBTQ+ marketing agency and consultancy, has launched T10 Insights, a new research and strategy offering designed to help brands engage queer consumers with cultural fluency, dimensional understanding, and strategic depth.
As marketing teams begin brand planning for 2026, the demand for authentic, forward-looking consumer insights has never been greater. LGBTQ+ audiences are reshaping the cultural and commercial landscape across nearly every category-from healthcare to CPG to entertainment and beyond. T10 Insights helps brands unlock this potential through a human-centered approach to LGBTQ+ consumer research, trend analysis, and cultural intelligence.
“T10 Insights is a natural evolution of what we’ve long delivered to our clients,” said Matt Tumminello, Founder and President of Target 10. “We’re formalizing a practice that already powers award-winning work and gives our partners a sharper read on culture, consumers, and growth opportunities at a time when the stakes, and expectations, have never been higher.”
What T10 Insights Offers
With a tailored mix of research, cultural insight, and strategic planning, T10 Insights equips clients to:
Conduct custom qualitative and quantitative research into LGBTQ+ identity, behavior, and experience
Surface cultural shifts and micro-movements through trend analysis and social listening
Identify whitespace and audience gaps through competitive audits
Translate insight into action at important junctures including brand strategy, positioning, campaign work, product innovation, and brand safety
A Human-Centered Approach to Cultural Intelligence
LGBTQ+ individuals now comprise 9.3% of U.S. adults and over 1 in 4 Gen Z adults-one of the fastest-growing segments with measurable influence and heightened brand loyalty when engaged. But the impact of inclusive messaging extends far beyond LGBTQ+ consumers. When brands speak with care and respect to queer people, they also connect with millions of additional consumers who respond strongly to LGBTQ+ inclusion in brand marketing- the friends and families of LGBTQ+ people and LGBTQ+ allies.
That ripple effect is why T10 Insights emphasizes not just audience understanding, but cultural relevance at scale, and an approach that is grounded in community-not just data. Clients don’t just receive findings; they gain meaning. Insights are synthesized through 25 years of LGBTQ+ expertise and translated into concrete brand action that can be integrated across marketing functions and scaled in step with broader marketing plans.
“Our edge isn’t just research-it’s resonance,” said Bob Friedman, Director of Strategy at Target 10. “We help brands see the full picture, read between the lines, and grow with opportunities that might otherwise be missed.”
Validated by Results, Rooted in Real Life
Target 10’s insight work has powered culturally fluent brand campaigns and innovation across pharma, beauty, personal care, sexual health and wellness, CPG, entertainment, food & beverage and more. From uncovering new LGBTQ+ audiences for brands like Trojan and Tylenol PM to shaping inclusive messaging and concept testing for weight loss, cancer, and HIV treatment brands, the work has led to recognition from the Association of National Advertisers, PRNews, Effie Awards, Shorty Awards, Anthem Awards and more.
It also informs the agency’s thought leadership and presence on industry stages-appearing in Forbes, TIME, Adweek, GLAAD, NBC News, Morning Consult, BuzzFeed, and the ANA’s Alliance for Inclusive and Multicultural Marketing (AIMM), among others.
What’s Next Starts With Understanding
T10 Insights reflects Target 10’s commitment to being two steps ahead-by listening closely, learning continuously, and exploring the full diversity of LGBTQ+ life and experiences.
As the marketplace evolves and competition for growth segments increases, brands with sharp insights into how queer consumers live, work and play will not only build stronger connections to those audiences, but long-term cultural relevance with all consumers in today’s world.
Explore T10 Insights and our full range of LGBTQ+ marketing and research services at https://target-10.com/our-services.
About Target 10
Target 10 is the leading LGBTQ+ marketing agency and consultancy, proudly serving some of the world’s largest brands and mission-driven organizations for over two decades. The agency specializes in research, strategy, creative, and content that authentically engages queer audiences and drives cultural relevance for its clients across a range of sectors, including CPG, healthcare, entertainment, and personal care.
In an effort to better educate patients and empower them to take the next step toward visual freedom, Brinton Vision has released a new, comprehensive Vision Correction Comparison Chart. The chart offers side-by-side comparisons of the most advanced refractive surgery options available today, including LASIK, SMILE, PRK, EVO ICL, and Custom Lens Replacement (CLR), as well as traditional options like glasses and contact lenses. As the only vision correction center of its kind in Missouri that offers all seven modern procedures under one roof, Brinton Vision is uniquely positioned to provide a full spectrum of information for patients exploring permanent solutions to rid yourself of glasses and contacts.
Many individuals researching vision correction are familiar with LASIK but are unaware of how far the field has evolved in recent years. This new chart is designed to eliminate confusion by presenting the facts in a simple, visual format, comparing technologies, recovery timelines, age ranges, prescription types, invasiveness, and long-term outcomes. The data-driven tool is accompanied by downloadable formats including a PNG image, PDF document, Google Sheet, and a full table view on the Brinton Vision website to make it accessible and easy to use across devices.
According to Dr. Jason Brinton, founder of Brinton Vision and Harvard-trained LASIK and refractive surgeon, the goal of the comparison chart is to give people the clarity they need to make confident choices about their vision. “Every eye is different, and there’s no such thing as a one-size-fits-all procedure when it comes to vision correction,” said Dr. Brinton. “This chart gives patients a starting point to understand their options and helps frame the conversation we have during their Brinton Vision Ocular Analysis.”
The chart breaks down meaningful differences between procedures that may appear similar at first glance. For example, both LASIK and SMILE reshape the cornea using laser technology, but SMILE is a minimally invasive procedure that avoids creating a corneal flap, making it ideal for patients with dry eyes or those who lead highly active lifestyles. LASIK, by contrast, offers faster visual recovery—often within one to two days—and can treat a broader range of prescriptions, including hyperopia, which SMILE cannot address. These distinctions matter when determining the right solution for a patient’s unique eyes, prescription, and lifestyle.
In another segment of the chart, LASIK is compared to EVO ICL, an implantable lens that offers a reversible option for individuals with high myopia or thinner corneas who may not qualify for laser procedures. EVO ICL avoids the creation of a corneal flap altogether and typically delivers excellent night vision while minimizing dry eye risk, making it an increasingly popular choice for patients in their 20s to 40s seeking a permanent yet non-destructive option. The comparison notes that while LASIK permanently alters the shape of the cornea, EVO ICL is a lens that can be removed later if needed, which is a significant differentiator for many patients weighing their comfort with permanent corneal changes.
The Vision Correction Comparison Chart also includes information about Custom Lens Replacement, also known as Refractive Lens Exchange. Unlike LASIK, which is typically suited for patients under 40, CLR is more appropriate for those over 40 who are beginning to experience presbyopia—the age-related loss of near vision—or are looking to eliminate the future need for cataract surgery. CLR replaces the eye’s natural lens with an artificial intraocular lens, addressing both distance and near vision, making it a preferred option for patients seeking a permanent, comprehensive solution.
Brinton Vision’s comparison also highlights PRK, a predecessor to LASIK that remains highly relevant today, especially for patients with thin corneas or those involved in contact sports. While the recovery time for PRK is longer than LASIK, and involves more initial discomfort, it avoids flap-related complications and still delivers excellent long-term visual outcomes. This procedure is often overlooked in the broader LASIK conversation, yet it plays a key role in customized treatment planning for certain candidates.
For patients trying to decide whether to pursue surgery or continue using glasses or contacts, the chart presents a financial and lifestyle contrast that is often eye-opening. Glasses and contact lenses may appear less expensive upfront but can cost thousands of dollars over a lifetime when factoring in lenses, frames, eye exams, and replacements. Vision correction surgery, though an investment, often pays for itself over time in both convenience and freedom. LASIK and other procedures eliminate daily maintenance and the frustrations that come with glasses fogging, slipping, or breaking, or contact lenses causing dryness and irritation.
In addition to the technical comparisons, the chart touches on monovision correction options. Monovision involves treating one eye for distance and the other for near vision and can be achieved through LASIK, PRK, SMILE, EVO ICL, or CLR. This strategy is commonly used for patients over 40 who want to reduce or eliminate the need for reading glasses. Brinton Vision offers monovision trials using contact lenses prior to surgery to ensure that patients can adapt to the unique experience, which involves a period of neural adaptation and adjustment in visual perception.
The Vision Correction Comparison Chart stands out not only for the depth of information it provides but also for how it reflects the philosophy of Brinton Vision—educating, empowering, and equipping patients to make informed decisions. Every person who visits the practice begins with a Brinton Vision Ocular Analysis, a diagnostic workup that uses state-of-the-art imaging to map the patient’s eyes in extraordinary detail. This data then informs a tailored recommendation from Dr. Brinton and his team, who walk patients through their results and discuss all seven vision correction options in the context of their individual needs.
For more information or to schedule a Brinton Vision Ocular Analysis, visit www.BrintonVision.com. To request an interview with Dr. Brinton or learn more about the new Vision Correction Comparison Chart, media inquiries can be directed to the Brinton Vision media relations team through the website’s contact page.
